GlassScriptPhysician profile
Wail Alnas
NPI 1215960786
$14,259.99
in general payments reported to CMS, 2019-2025
67 companies · $2,389 in 2025
The $2,389 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,664 · 2020: $2,748 · 2021: $647 · 2022: $1,637 · 2023: $2,908 · 2024: $2,269 · 2025: $2,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,693 · Travel and Lodging: $610 · Consulting Fee: $175 · Education: $86.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,692.83 |
| Travel and Lodging | $610.30 |
| Consulting Fee | $175.00 |
| Education | $86.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,652.43 | 2019-2025 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $1,015.49 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Novartis Pharmaceuticals Corporation | $842.92 | 2019-2025 | |
| Pfizer INC. | $811.72 | 2019-2025 | |
| Exelixis INC. | $737.66 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $567.07 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Astellas Pharma US INC | $542.23 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Merck Sharp & Dohme LLC | $531.77 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Gilead Sciences, INC. | $497.37 | 2021-2025 | Trodelvy |
| Amgen INC. | $447.97 | 2019-2022 | |
| Janssen Biotech, INC. | $435.08 | 2019-2025 | Erleada, Talvey, Rybrevant |
| Celgene Corporation | $432.00 | 2019-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $308.51 | 2019-2025 | Tecentriq, Polivy, Itovebi |
| Lilly USA, LLC | $241.53 | 2019-2025 | Verzenio, Jaypirca |
| Eisai INC. | $224.62 | 2019-2024 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $224.43 | 2019-2024 | |
| Glaxosmithkline, LLC. | $220.71 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Abbvie INC. | $219.71 | 2022-2025 | Venclexta |
| Incyte Corporation | $199.59 | 2019-2025 | Monjuvi, Jakafi |
| Alexion Pharmaceuticals, INC. | $191.34 | 2023-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $184.78 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $176.37 | 2022-2025 | Libtayo |
| Beigene USA, INC. | $127.94 | 2021-2024 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $123.25 | 2022-2024 | Monoferric |
| Dendreon Pharmaceuticals LLC | $115.56 | 2023 | Provenge |
| Stemline Therapeutics INC. | $114.53 | 2023-2025 | Orserdu |
| Seagen INC. | $113.13 | 2019-2023 | Adcetris, Tivdak |
| Servier Pharmaceuticals LLC | $111.50 | 2024-2025 | |
| Array Biopharma INC | $109.00 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Rigel Pharmaceuticals, INC. | $103.25 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Adaptive Biotechnologies Corporation | $101.96 | 2023-2025 | Clonoseq |
| Tempus Ai, INC | $101.68 | 2024-2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.01 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.93 | 2019-2025 | |
| Kite Pharma, INC. | $93.41 | 2022-2025 | Yescarta |
| Global Blood Therapeutics, INC. | $91.10 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.66 | 2022-2025 | Iclusig, Ninlaro |
| Pharmacyclics LLC, An Abbvie Company | $78.61 | 2019-2023 | Imbruvica |
| Taiho Oncology, INC. | $71.50 | 2022-2025 | |
| Genzyme Corporation | $68.31 | 2019-2024 | |
| Genmab U.S., INC. | $58.50 | 2023-2025 | Epkinly |
| Emd Serono, INC. | $51.29 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $46.02 | 2024-2025 | Qinlock, Romvimza |
| Morphosys, US INC. | $45.41 | 2021-2023 | Monjuvi |
| Geron Corporation | $41.81 | 2025 | Rytelo |
| Coherus Oncology, INC. | $41.18 | 2020-2024 | |
| Sobi, INC | $37.72 | 2024-2025 | |
| Beone Medicines USA, INC. | $37.64 | 2025 | Brukinsa |
| Verastem, INC. | $35.67 | 2019 | |
| Tersera Therapeutics LLC | $34.79 | 2023 | Zoladex |
| Secura Bio, INC. | $33.67 | 2022 | |
| Aveo Pharmaceuticals, INC. | $29.03 | 2022 | |
| Tesaro, INC. | $23.71 | 2019 | |
| Ge Healthcare | $22.47 | 2024 | |
| Pharmaessentia USA Corporation | $21.22 | 2025 | Besremi |
| Legend Biotech USA INC. | $17.96 | 2025 | Carvykti |
| Apellis Pharmaceuticals, INC. | $17.92 | 2024 | Empaveli |
| Adc Therapeutics America, INC. | $16.94 | 2024 | |
| Novocure INC. | $15.76 | 2025 | Optune Lua (Novottf-200t) |
| Karyopharm Therapeutics INC. | $15.62 | 2022 | |
| Blueprint Medicines Corporation | $15.50 | 2021 | |
| Clovis Oncology, INC. | $15.09 | 2019 | |
| Agios Pharmaceuticals, INC. | $14.75 | 2025 | Pyrukynd |
| G1 Therapeutics, INC. | $14.58 | 2023 | Cosela |
| Sanofi-Aventis U.S. LLC | $13.92 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $13.50 | 2020 | |
| Acceleron Pharma, INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wail Alnas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.